In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...
TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...
In a recent study published in the journal Science Advances, researchers in Sweden conducted virtual screens of over 16 million compounds using multiple receptor models developed by AlphaFold and ...
The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic activity of ACCG-2671 in both healthy volunteers and individuals with obesity. The study will ...
A one-day national-level workshop on “Drug Designing, Molecular Docking and Simulations” was held today at the BRIC–Institute of Bioresources and Sustainable Development (IBSD), Takyelpat, ...
An illustration of an algorithm predicting a protein structure, with digitized blocks on the left becoming ribbons on the right. An illustration of the RoseTTAFold software predicting a protein ...
Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback